Question Bank › Nobody is coming: management describes a market

Nobody is coming: management describes a market it must build itself, and the first buyers have started paying

Calls Tested
466
Answered YES
8
Hit Rate
1.7%
rare by design

Green Plains Inc. (GPRE) — this company's answers

NO on the Q4 2023 call 2024-02-07 F
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司正在创造一个新市场,即主要障碍不是竞争或价格,而是买家需要被教育、转化、认证或改变习惯,并且这种转化工作已经开始成功,有实际付费买家。 在电话会议中,Todd Becker多次提到: - 关于60%蛋白产品,他们正在进行商业饲料试验,与潜在客户谈判,并开始向欧洲、中东、亚洲销售,但强调这是新产品,需要建立供应链,并确保获得合理价格。他说“我们正在执行必要的步骤来开发大规模项目,包括建立全球供应链,并确保我们为产品价值获得报酬。”他还说“我们相信这不是是否的问题,而是何时的问题。”这表明他们正在教育市场,但尚未大规模销售。 - 关于清洁糖(dextrose),他说“我们正在与几个现有对手方进行后期谈判,涉及我们未来几年生产的很大一部分。”但尚未宣布商业协议。 - 关于碳捕获,他说“我们预计在2025年中期上线”,但尚未有实际收入。 然而,在回答关于市场创造的问题时,管理层是否明确表示他们正在创造市场?他们提到“我们正在接近60%蛋白的商业协议”,但尚未达成。他们提到“我们有一些60%蛋白的商业销售,数量较小”,但这是开始。他们提到“我们正在完成一些商业饲料试验”,但尚未完成。 关键点:管理层是否描述了一个需要改变买家习惯的市场?他们提到“这是一个全新的产品,我们也是新供应商,所以很多事情必须建立起来才能进行大规模项目,包括全新的端到端供应链。”这确实表明他们需要教育市场。但关于转化是否成功,他们提到“我们已经开始向欧洲、中东和亚洲销售60%蛋白”,但这是“较小数量”。他们还说“我们正在接近一些商业协议”,但尚未签署。 在清洁糖方面,他们说“我们预计在第二季度初开始交付产品”,但尚未交付。他们提到“我们正在与几个对手方进行后期谈判”,但尚未达成。 因此,管理层描述的是市场创造工作,但转化是否已经成功?他们提到有实际销售,但规模很小。他们提到“我们有一些60%蛋白的商业销售”,但这是开始。他们提到“我们正在接近商业协议”,但尚未完成。 问题要求:管理层是否描述了一个单一情况,即公司正在做市场创造工作,并且这种转化已经开始成功,有实际付费买家?从记录看,他们确实有少量销售,但主要工作仍在进行中。他们提到“我们正在接近商业协议”,但尚未达成。他们提到“我们有一些60%蛋白的商业销售”,但这是“较小数量”。他们提到“我们正在完成商业饲料试验”,但尚未完成。 因此,转化工作尚未大规模成功,只是开始。问题要求“present-tense reality”和“real orders, customers, deployments, or usage happening now”。他们确实有少量销售,但主要障碍仍然是教育市场。然而,他们明确表示“我们正在接近商业协议”,这表明尚未完全成功。 此外,关于清洁糖,他们尚未开始交付。关于碳捕获,尚未上线。 因此,我认为管理层描述的是市场创造工作,但转化尚未大规模成功,只是有初步迹象。问题要求“has just started to win that argument at scale”,但这里只是开始,尚未大规模。 然而,他们提到“我们有一些60%蛋白的商业销售”,这算是有实际买家。但数量较小。他们提到“我们正在接近商业协议”,这表明尚未达成。 我认为答案应该是NO,因为转化尚未真正成功,只是有初步迹象,而且主要障碍仍然是教育市场,但尚未有大规模付费买家。 但让我们再仔细看:他们提到“我们有一些60%蛋白的商业销售”,这是实际销售。他们提到“我们正在接近商业协议”,但尚未达成。他们提到“我们正在完成商业饲料试验”,但尚未完成。所以,有实际销售,但规模很小。 问题要求“conversion is now actually working, with money behind it”,并且“real orders, customers, deployments, or usage happening now”。他们确实有订单,但很小。然而,他们主要描述的是“接近”和“正在谈判”,而不是已经成功。 因此,我认为答案应为NO,因为管理层没有明确表示转化已经成功,而是仍在进行中。 但让我们看看是否有其他部分。关于清洁糖,他们尚未交付。关于碳捕获,尚未上线。所以,只有60%蛋白有少量销售。 因此,答案应为NO。

← Back to the full GPRE analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe the company as CREATING A MARKET THAT DOES NOT YET PROPERLY EXIST — that is, does management convey that the main obstacle in front of the business is not competition or price but the fact that the buyers themselves must first be TAUGHT, CONVERTED, QUALIFIED, OR HAVE THEIR OWN HABITS AND SYSTEMS CHANGED before they can buy at all — AND does management report that this conversion work has now begun to succeed with real paying buyers in the recent period? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with both halves present as a present-tense reality: (1) THE COMPANY IS DOING MARKET-CREATION WORK, NOT MARKET-SHARE WORK. Management describes effort spent on getting the world ready to buy, rather than on beating rivals for demand that already exists. Any genuine expression of this counts, and the form varies widely across industries — for example: management explaining that customers must be educated on a category, method, material, or approach they do not yet understand or trust; that buyers have to change an entrenched practice, workflow, standard, specification, protocol, or supply arrangement in order to adopt; that the company is spending its time training, certifying, demonstrating, running side-by-side comparisons, or working through customers' internal validation, testing, trial, or approval processes; that adoption is slow because decision-makers have never bought anything like this and there is no existing budget line, reimbursement path, permitting route, or procurement category for it; that the company is having to build the surrounding conditions of its own market — installers, prescribers, applicators, inspectors, dealers, code acceptance, industry awareness, or downstream capability — before volume can flow; or that the company's chief competitor is inertia, the status quo, or "the way it has always been done" rather than another vendor. Management should convey that this conversion problem, rather than winning a competitive bid, is what actually governs how fast the business grows. (2) THE CONVERSION IS NOW ACTUALLY WORKING, WITH MONEY BEHIND IT. Management points to concrete evidence from the recent period that the resistance is giving way and buyers are crossing over: converts who have moved from the old way to the company's way and are now purchasing; customers who completed their evaluation, testing, or internal approval and have begun ordering; adoption spreading from the earliest believers to more conventional or larger buyers; practices, specifications, or standards beginning to be written the company's way; or the pace of conversions picking up relative to what the company used to achieve. The evidence must be present-tense and paid — real orders, customers, deployments, or usage happening now — not merely interest, education efforts underway, or a large market management believes exists. The essence is ONE phenomenon: a company whose growth is gated by how fast it can change other people's minds and habits, which has just started to win that argument at scale. The industry, the entrenched habit being displaced, and the form of the conversion may vary widely. Answer NO if the company competes for demand that plainly already exists — bidding, winning share, out-selling rivals, or serving an established buying pattern — however well it is doing. NO if management merely asserts a large addressable market, a superior product, or that customers "just need to see it," without describing an adoption barrier of habit, understanding, qualification, or established practice that must be overcome first. NO if the education, trialing, or qualification work is described with nothing yet converting into paying business — pilots without orders, interest without commitment, a market being "developed" with no crossings to point to. NO if the conversion described is chiefly the company's own customers upgrading to its newer product generation rather than outsiders changing their existing practice. NO if the barrier described is purely a pending external approval or a single regulatory gate with no buyer-behavior change involved. NO if management is chiefly explaining that adoption has stalled, slowed, or proven harder than expected with no recent progress. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CALX Calix, Inc. Q1 2023 2023-04-20 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
HLNE Hamilton Lane Incorporated Q1 2023 2022-08-02 C+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ALKS Alkermes plc Q3 2018 2018-10-23 C
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C

How the model reasoned

ILMN · Q1 2018 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing Illumina's growth as market creation in the "earliest stages of the genomics journey," where the core obstacle is buyer education, habit change, and qualification rather than competing for existing demand. They describe heavy investment in studies (Harvard Pilgrim NIPT, MiSeq rugged, UK Biobank, 100k Genomes) to generate clinical/economic evidence for payers and physicians, regulatory progress (CMS NCD, FDA 23andMe BRCA approval), and expanding reimbursement paths. This is explicitly positioned as overcoming inertia and entrenched practices ("the way it has always been done") before volume flows.
EXFY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, with both market-creation work and successful conversion with paying buyers. YES The transcript shows David Barrett describing the SMB expense-management market as "largely untouched" with "hundreds of millions of businesses" where "virtually none of them do anything," positioning Expensify as the first to introduce concepts like real-time expense scanning and pre-accounting through ExpensiCon to educate and change accounting-industry habits. This frames the core obstacle as buyer conversion and habit change rather than direct rivalry. He contrasts this with competitors retreating to enterprise sales due to defaults and cost pressures, while Expensify's bottom-up model and Free Plan enable early-stage onboarding.
SGRY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing the core growth driver as a site-of-care shift that requires buyers (physicians, payers, patients) to change entrenched habits and systems: physicians must be recruited and trained to perform procedures in ASCs rather than hospitals; payers must adopt value-based incentives and capitated models to move volume 5-figure discounts; patients must accept lower-cost, high-quality outpatient settings. This is presented as the primary obstacle to faster growth, not competitive bidding for already-existing demand.

More from the question bank

Insulated through the downturnThe bridge is already builtManagement volunteers specific, checkable nuScarcity of the company's own outputThe company is being paid to solve a problemBet-the-company financing already spent on hAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.